HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
复制标题

DOI:
10.1586/era.10.226
复制
发表时间:
2011-02
影响因子:
3.3
通讯作者:
Chandarlapaty S
Chandarlapaty S
中科院分区:
医学3区
文献类型:
--
作者:
Gajria D;Chandarlapaty S

文献摘要

参考文献

被引文献

相似文献

HER2 amplification is seen in up to 20% of breast cancers and is associated with an aggressive phenotype. Trastuzumab, a monoclonal antibody to HER2, accrues significant clinical benefit in the metastatic and adjuvant settings. However, some patients suffer disease recurrence despite adjuvant trastuzumab therapy, and many patients with metastatic disease do not respond to therapy or develop refractory disease within 1 year of treatment. Given the increased recognition of de novo and acquired resistance to therapy, considerable research has been dedicated to understanding the molecular mechanisms of trastuzumab resistance. Here, we highlight putative models of resistance, including activation of the downstream PI3K-signaling pathway, accumulation of a constitutively active form of HER2, and crosstalk of HER2 with other growth factor receptors. The identification of these specific mechanisms of trastuzumab resistance has provided a rationale for the development of several novel HER2-targeted agents as the mechanisms have largely suggested a continued tumor dependence on HER2 signaling. We explore the emerging data for the treatment of trastuzumab-refractory disease with novel agents including lapatinib, neratinib, pertuzumab, trastuzumab-DM1, HSP90 and PI3K pathway inhibitors, and the future potential for these inhibitors which, if combined with reliable biomarkers of resistance, may ultimately usher in a new era of personalized medicine for this disease.
HSP90 抑制剂可阻断曲妥珠单抗耐药肿瘤中的 p95-HER2 信号传导并抑制其生长。
DOI: 10.1038/onc.2009.337
发表时间: 2010-01-21
期刊: ONCOGENE
影响因子: 8
作者:
Chandarlapaty, S.;Scaltriti, M.;Angelini, P.;Ye, Q.;Guzman, M.;Hudis, C. A.;Norton, L.;Solit, D. B.;Arribas, J.;Baselga, J.;Rosen, N.
通讯作者: Rosen, N.
DOI: 10.1093/annonc/mdn759
发表时间: 2009-06-01
期刊: ANNALS OF ONCOLOGY
影响因子: 50.5
作者:
Blackwell, K. L.;Pegram, M. D.;Burstein, H. J.
通讯作者: Burstein, H. J.
DOI: 10.1200/jco.2005.66.130
发表时间: 2005-08-10
影响因子: 45.3
作者:
Chan, S;Scheulen, ME;Moore, L
通讯作者: Moore, L
DOI: 10.1200/jco.1999.17.9.2639
发表时间: 1999-09-01
影响因子: 45.3
作者:
Cobleigh, MA;Vogel, CL;Slamon, DJ
通讯作者: Slamon, DJ
DOI: 10.1016/s1535-6108(02)00097-1
发表时间: 2002-08-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Agus, DB;Akita, RW;Sliwkowski, MX
通讯作者: Sliwkowski, MX